IXICO plc is a brain health company. The Company's brain health focus includes Alzheimer's disease, Huntington's disease, Parkinson's disease, behavioral health and adolescent mental health. It is a provider of clinical trials services to pharmaceutical companies. Its products include Assessa, mehealth, MyBrainBook and TrialTracker. Assessa is a decision-support tool for healthcare professionals looking to diagnose dementia and detect the underlying causes. mehealth is an online software for clinicians at the point-of-care to support decision making and improve the monitoring and treatment of patients. MyBrainBook is a digital platform to improve the quality of life and service delivery for people living with dementia and their supporters. TrialTracker is a Web-based system that allows users to track their imaging-based research study or clinical trial in real time. It is also collaborating with partners to develop companion digital health products.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: LON:IXI
- CUSIP: N/A
- Web: ixico.com
Capitalization:- Market Cap: £8.56 million
- Outstanding Shares: 26,736,000
Average Prices:- 50 Day Moving Avg: GBX 30.51
- 200 Day Moving Avg: GBX 31.16
- 52 Week Range: GBX 22 - GBX 44
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: £3.59 million
- Price / Sales: 2.38
- Book Value: GBX 0.14 per share
- Price / Book: 2.29
Profitability:- EBIDTA: ($1,130,000.00)
- Net Margins: -33.90%
- Return on Equity: -35.21%
- Return on Assets: -24.82%
Misc:- Average Volume: 3,305 shs.
Frequently Asked Questions for Ixico Plc (LON:IXI)
What is Ixico Plc's stock symbol?
Ixico Plc trades on the London Stock Exchange (LON) under the ticker symbol "IXI."
Who are some of Ixico Plc's key competitors?
Some companies that are related to Ixico Plc include RXi Pharmaceuticals Corporation (RXII), AEterna Zentaris (AEZS), Novogen Limited (NVGN), OncoGenex Pharmaceuticals (OGXI), Jaguar Animal Health (JAGX), Repros Therapeutics (RPRX), Roka Bioscience (ROKA), Transgenomic (PRPO), Metabolix (YTEN), Akers Biosciences (AKR), Synairgen plc (SNG), Ampliphi Biosciences Corp (APHB), Rosetta Genomics (ROSG), Anacor Pharmaceuticals (ANAC), ANI Pharmaceuticals (BPAX), Celator Pharmaceuticals (CPXX), Cellular Dynamics International (ICEL) and Covance (CVD).
Who are Ixico Plc's key executives?
Ixico Plc's management team includes the folowing people:
- Giulio Cerroni, Chief Executive Officer, Director
- Susan Day Lowther, Chief Financial Officer
- Michelle Lax, Vice President - Clinical Operations
- Derek Hill Ph.D., Executive Director
- Jane Whitrow, Secretary
- Charles Spicer, Non-Executive Chairman of the Board
- Maina Bhaman, Non-Executive Director
- John Bradshaw, Non-Executive Director
- Mark Robert Warne, Non-Executive Director
- Tim Sharpington, Senior Non-Executive Independent Director
How do I buy Ixico Plc stock?
Shares of Ixico Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Ixico Plc's stock price today?
One share of Ixico Plc stock can currently be purchased for approximately GBX 32.
MarketBeat Community Rating for Ixico Plc (LON IXI)MarketBeat's community ratings are surveys of what our community members think about Ixico Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Ixico Plc (LON:IXI) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Ixico Plc (LON:IXI)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Ixico Plc (LON:IXI)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Ixico Plc (LON:IXI)Current Year EPS Consensus Estimate: $-4.10 EPS
Dividend History for Ixico Plc (LON:IXI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ixico Plc (LON:IXI)Insider Trades by Quarter for Ixico Plc (LON:IXI)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/1/2016 | Lowther,Susan | Insider | Buy | 28,366 | GBX 35 | £9,928.10 | |
| 2/4/2016 | Hill,Derek | Insider | Buy | 10,000 | GBX 39 | £3,900 | |
| 2/3/2016 | Richards,Andrew | Insider | Buy | 45,899 | GBX 33 | £15,146.67 | |
(Data available from 1/1/2013 forward)
Headline Trends for Ixico Plc (LON:IXI)
Latest Headlines for Ixico Plc (LON:IXI)
| Source: |
|
Ixico Plc (IXI) Chart for Thursday, July, 20, 2017
